The three GLP-1 medications approved by the FDA to treat obesity include: Liraglutide (Saxenda/Victoza) Semaglutide (Wegovy/Ozempic/Rybelsus) Tirzepatide (Zepbound/Mounjaro) GLP-1 medications can lead to an average weight loss of 10% to 20% over 12-24 months when used alongside healthy diet and exercise changes
This, combined with the rising prevalence of diabetes and evolving treatment needs in metabolic diseases, makes them a growing field of interest
Multiple rodent models of PCOS, capitalizing mainly on the impact of androgen excess at different developmental windows, with variable penetrance in terms of reproductive and metabolic impairment, have been used in translational studies, in order to capture the phenotypic heterogeneity of the syndrome 38
Semaglutide, tirzepatide, and retatrutide work on different receptors, and the mechanism difference explains the outcome difference
Because they significantly reduce appetite, several GLP-1 medications are now FDA-approved for chronic weight management in adults with obesity or overweight with related health conditions
Zepbound coverage may follow different pathways depending on the FDA-approved indication, plan rules, diagnosis, and documentation
